Verona

• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL … Ended recruitment
  2024-511627-34-00 4 2024-10-17 Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous … Ended recruitment
  2024-511195-33-00 3 2024-09-23 Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended recruitment
  2022-501452-29-00 9 2024-08-28 Metastatic Non-small Cell Lung Cancer
• Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al … Ended recruitment
  2023-505673-32-00 5 2024-08-05 Hypophosphatasia
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended recruitment
  2023-505435-12-00 5 2024-06-04 Asthma
• REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended recruitment
  2023-509026-21-00 6 2024-06-03 severe asthma
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca … Ended recruitment
  2023-507995-33-00 9 2024-05-23 MSI-H/dMMR Gastric cancer
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended recruitment
  2023-507333-17-00 5 2024-04-15 HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
• Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea … Ended recruitment
  2023-503385-24-00 4 2024-03-12 Asthma
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidit … Ended recruitment
  2023-504413-80-00 5 2023-12-07 Obesity
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended recruitment
  2023-509143-27-00 7 2023-11-27 Locally advanced or metastatic solid tumor malignancies, platinum resi
• A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi … Ended recruitment
  2023-503294-37-00 5 2023-11-20 Osteogenesis Imperfecta
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He … Ended recruitment
  2023-503422-39-00 5 2023-10-20 Hepatocellular Carcinoma (HCC)

Showing 265–288 of 440 trials